Cannabis News

Cannabis Investing

Revive Therapeutics announced the appointment of Dr. Arun Sanyal as a scientific advisor for their cannabinoid-based therapeutics targeting liver diseases.

Revive Therapeutics (TSXV:RVV; OTCQB:RVVTF) announced the appointment of Dr. Arun Sanyal as a scientific advisor for their cannabinoid-based therapeutics targeting liver diseases.
As quoted in the press release:

“I am pleased that Dr. Sanyal has joined Revive to assist with advancing the research and clinical development of our cannabinoid-based research initiatives targeting liver diseases,” said Craig Leon, Chief Executive Officer of Revive. “Dr. Sanyal will be valuable in guiding our liver diseases product pipeline in a number of indications including liver cirrhosis, non-alcoholic steatohepatitis and non-alcoholic fatty liver disease.”
“I look forward to working with Revive Therapeutics on the broad areas of hepatic inflammation, fibrosis and cirrhosis particularly in the context of non-alcoholic fatty liver disease. I am particularly pleased to be working on the role of the cannabinoid system and non-alcoholic fatty liver disease, two areas of long standing research interest for me,” said Dr. Arun Sanyal.

Click here to read the full press release.

Source: www.marketwired.com

RVV:CC

MARKETS

Markets
TSX19062.91+345.79
TSXV647.33+15.54
DOW31500.68+823.32
S&P 5003911.74+116.01
NASD11607.62+375.43
ASX6528.40+19.90

COMMODITIES

Commodities
Gold1838.64+7.63
Silver21.50+0.36
Copper3.78+0.03
Palladium1930.50+53.50
Platinum914.50+3.50
Oil107.21-0.41
Heating Oil4.18-0.06
Natural Gas6.10-0.12

DOWNLOAD FREE REPORTS

×